11,044 Results

FDA accepts BLA for enfortumab vedotin to treat bladder cancer.- Seattle Genetics.

 Added 21 hours ago

Seattle Genetics, Inc announced that the FDA has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin...

Alnylam Pharma initiates APOLLO-B phase III trial of Onpattro to treat transthyretin amyloidosis with cardiomyopathy.

 Added 21 hours ago

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the Company has initiated APOLLO-B, a global Phase III placebo-controlled...

SUSTAIN 8 and 10 Phase III trials of Ozempic show Ozempic superior in type 2 diabetes.- Novo Nordisk

 Added 21 hours ago

Novo Nordisk announced the results from two Ozempic (once-weekly semaglutide 1.0 mg) head-to-head Phase III clinical trials, SUSTAIN 8 and...

Positive phase III PREVENT trial of Cosentyx to treat non-radiographic axial spondyloarthritis.-Novartis

 Added 21 hours ago

Novartis, announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with...

VP 102 filed with FDA for molluscum contagiosum.- Verrica Pharma

 Added 1 day ago

Verrica Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for VP 102 (cantharidin 0.7% Topical Solution), a...

Purdue Pharma files for bankrupcy

 Added 1 day ago

On September 15, 2019 and September 16, 2019, Purdue Pharma L.P. and 23 affiliated debtors (collectively, the "Debtors") each filed...

Lundbeck to acquire Alder Biopharmaceuticals and with it eptinezumab for migraine prevention

 Added 1 day ago

H. Lundbeck A/S and Alder BioPharmaceuticals announced a definitive agreement for Lundbeck to acquire Alder. Under the terms of the...

Tremfya filed with FDA for psoriatic arthritis.- Janssen Pharma

 Added 1 day ago

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the...

Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed

 Added 1 day ago

Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how...

Castle Creek Holdings to acquire Fibrocell Science Inc.and with it FCX 007 a proposed treatment for epidermolysis bullosa

 Added 2 days ago

Castle Creek Pharmaceutical Holdings, Inc. announced it has reached an agreement to acquire Fibrocell Science, Inc. a cell and gene...

Load more